Graft Polymer (UK) PLC (GB:GPL) has released an update.
Graft Polymer (UK) PLC has achieved significant milestones in its joint venture with Awakn Life Sciences Corp., including identifying promising new compounds for treating trauma-related disorders like PTSD, establishing efficient synthesis pathways, and filing a provisional patent. Partnering with Charnwood Discovery for synthesis services, the collaboration aims to advance these novel therapeutics towards the market, signaling a major step forward in the development of new treatments for mental health disorders.
For further insights into GB:GPL stock, check out TipRanks’ Stock Analysis page.
